加味丹参饮对老年轻、中度高血压伴心肌梗死患者 心肌功能的保护作用观察(1)
〔摘要〕 目的 觀察加味丹参饮对老年轻、中度高血压伴心肌梗死患者心肌功能的保护作用。方法 选取80例高血压伴心肌梗死的老年患者，按随机数字表法分为观察组与对照组各40例。对照组患者予以酒石酸美托洛尔片、贝那普利氢氯噻嗪片、缬沙坦片、辛伐他汀胶囊、阿司匹林肠溶片进行治疗；观察组在对照组基础上联合加味丹参饮进行治疗，两组均治疗6个月。比较两组治疗前后的左心室射血分数(LVEF)、左室壁运动指数(WMSI)、血浆脑钠钛(BNP)水平，治疗前、治疗3 个月、治疗6个月的心肌梗死面积，治疗期间心肌不良事件发生情况与不良反应总发生率。结果 两组治疗后的LVEF较治疗前均显著升高、WMSI与血清BNP水平较治疗前均显著降低(P<0.05)。观察组治疗后的LVEF显著高于对照组、WMSI与血清BNP水平显著低于对照组(P<0.05)。两组治疗3个月及6个月的心肌梗死面积较治疗前均显著下降(P<0.05)，且观察组显著低于对照组(P<0.05)。观察组心肌不良事件发生率为2.5%，显著低于对照组20.0%(P<0.05)。观察组与对照组不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 加味丹参饮治疗老年轻、中度高血压伴心肌梗死患者可有效缩小心肌梗死范围，保护心肌功能，减少心肌不良事件的发生，且安全可靠，值得推广。
〔关键词〕 高血压；心肌梗死；加味丹参饮；心肌功能
〔中图分类号〕R289.3；R259 〔文献标志码〕B 〔文章编号〕doi：10.3969/j.issn.1674-070X.2018.05.023
Protective Effect of Modified Danshen Decoction on Myocardial Function in Elderly Patients with Mild to Moderate Hypertension and Myocardial Infarction
FENG Zhong1， ZHANG Darui1， ZHONG Qiaoyan1， MA Junqi2*
(1. Urumqi Hospital of Traditional Chinese Medicine， Urumqi， Xinjiang 830000， China；
2. Emergency Center， Xinjiang Autonomous Region Hospital of Traditional Chinese Medicine， Urumqi， Xinjiang 830099， China)
〔Abstract〕 Objective To observe the protective effect of Modified Danshen decoction on myocardial function in elderly patients with mild to moderate hypertensive myocardial infarction. Methods A total of 80 cases of elderly hypertensive patients with myocardial infarction were selected and randomly divided into observation group and control group with 40 cases in each group. Patients in the control group were treated with metoprolol tartrate tablets， benazepril hydrochlorothiazide tablets， valsartan tablets， simvastatin capsules and aspirin enteric-coated tablets. The observation group was administrated with modified Danshen decoction on the basis of control group. The treatment course was for 6 months. The left ventricular ejection fraction (LVEF)， left ventricular wall motion index (WMSI) and plasma brain natriuretic peptide (BNP) levels before and after treatment， the infarct size at before treatment， after treatment for 3 months and 6 months， the adverse cardiac events and the incidence of adverse events during the treatment were compared between the two groups. Results The LVEF of both groups increased significantly after treatment than before treatment， and WMSI and serum BNP levels were significantly lower than before treatment (P<0.05). The LVEF in the observation group was significantly higher than that in the control group， and the levels of WMSI and serum BNP were significantly lower than those in the control group (P<0.05). The infarct size at treatment for 3 months and 6 months in both groups was significantly lower than that before treatment (P<0.05). The infarct size in observation group at 3 months and 6 months which were significantly lower than the control group. The incidence of myocardial adverse events in the observation group was 2.5%， which was significantly lower than 20.0% in the control group (P<0.05). The total incidence of adverse reactions in observation group and control group were statistically significant (P>0.05). Conclusion The modified Danshen decoction shows a safe and reliable effect in treatment of elderly patients with mild to moderate hypertensive myocardial infarction， which could effectively reduce myocardial infarction， myocardial function， reduce myocardial adverse events， worthy of promoting., 百拇医药(冯忠 张大锐 钟巧燕)
〔关键词〕 高血压；心肌梗死；加味丹参饮；心肌功能
〔中图分类号〕R289.3；R259 〔文献标志码〕B 〔文章编号〕doi：10.3969/j.issn.1674-070X.2018.05.023
Protective Effect of Modified Danshen Decoction on Myocardial Function in Elderly Patients with Mild to Moderate Hypertension and Myocardial Infarction
FENG Zhong1， ZHANG Darui1， ZHONG Qiaoyan1， MA Junqi2*
(1. Urumqi Hospital of Traditional Chinese Medicine， Urumqi， Xinjiang 830000， China；
2. Emergency Center， Xinjiang Autonomous Region Hospital of Traditional Chinese Medicine， Urumqi， Xinjiang 830099， China)
〔Abstract〕 Objective To observe the protective effect of Modified Danshen decoction on myocardial function in elderly patients with mild to moderate hypertensive myocardial infarction. Methods A total of 80 cases of elderly hypertensive patients with myocardial infarction were selected and randomly divided into observation group and control group with 40 cases in each group. Patients in the control group were treated with metoprolol tartrate tablets， benazepril hydrochlorothiazide tablets， valsartan tablets， simvastatin capsules and aspirin enteric-coated tablets. The observation group was administrated with modified Danshen decoction on the basis of control group. The treatment course was for 6 months. The left ventricular ejection fraction (LVEF)， left ventricular wall motion index (WMSI) and plasma brain natriuretic peptide (BNP) levels before and after treatment， the infarct size at before treatment， after treatment for 3 months and 6 months， the adverse cardiac events and the incidence of adverse events during the treatment were compared between the two groups. Results The LVEF of both groups increased significantly after treatment than before treatment， and WMSI and serum BNP levels were significantly lower than before treatment (P<0.05). The LVEF in the observation group was significantly higher than that in the control group， and the levels of WMSI and serum BNP were significantly lower than those in the control group (P<0.05). The infarct size at treatment for 3 months and 6 months in both groups was significantly lower than that before treatment (P<0.05). The infarct size in observation group at 3 months and 6 months which were significantly lower than the control group. The incidence of myocardial adverse events in the observation group was 2.5%， which was significantly lower than 20.0% in the control group (P<0.05). The total incidence of adverse reactions in observation group and control group were statistically significant (P>0.05). Conclusion The modified Danshen decoction shows a safe and reliable effect in treatment of elderly patients with mild to moderate hypertensive myocardial infarction， which could effectively reduce myocardial infarction， myocardial function， reduce myocardial adverse events， worthy of promoting., 百拇医药(冯忠 张大锐 钟巧燕)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 冠状动脉病 > 心肌梗塞